DDInter48 DDInter178
Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout. It was initially approved by the FDA in 1966 and is now formulated by several manufacturers.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Allopurinol {u} (Compound) treats {v} (Disease) gout
Allopurinol {u} (Compound) binds {v} (Gene) SLC22A8
Allopurinol {u} (Compound) is included by {v} (Pharmacologic Class) Xanthine Oxidase Inhibitors
Allopurinol {u} (Compound) causes {v} (Side Effect) Retinitis
Allopurinol (Compound) treats gout (Disease)
Allopurinol (Compound) binds SLC22A8 (Gene)
Allopurinol (Compound) is included by Xanthine Oxidase Inhibitors (Pharmacologic Class)
Allopurinol (Compound) causes Retinitis (Side Effect)